Strength Seen in Agenus (AGEN): Stock Soars 17.2% – Tale of the Tape

December 19, 2014 Technicals 0

Zacks

Agenus Inc. (AGEN) was a big mover last session with its shares rising over 7% on the day. The upside was owing to its partner GlaxoSmithKline’s (GSK) announcement that the ZOE-50 Phase 3 study on the novel candidate vaccine HZ/su has met its primary endpoint. This development led to far more shares changing hands yesterday than in a normal session. This continues the recent uptrend of the company as the stock has gained roughly 33% in the past one-month time frame.

This biopharmaceutical company has seen 1 positive estimate revision in the last 60 days. The Zacks Consensus Estimate has also moved higher over the same period. This implies solid trading potential for the company. So make sure to keep an eye on this stock going forward to see if yesterday’s rally can turn into more strength down the road.

Agenus currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.

Be the first to comment

Leave a Reply